JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Sana Biotechnology Inc

Closed

SectorHealthcare

5.58 1.64

Overview

Share price change

24h

Current

Min

5.41

Max

5.68

Key metrics

By Trading Economics

Income

-44M

-94M

Profit margin

-321.09

Employees

194

EBITDA

-48M

-95M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+50% upside

Dividends

By Dow Jones

Next Earnings

7 Nov 2025

Market Stats

By TradingEconomics

Market Cap

689M

1.4B

Previous open

3.94

Previous close

5.58

News Sentiment

By Acuity

50%

50%

163 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Sana Biotechnology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

23 Oct 2025, 20:49 UTC

Earnings

Correction to Thermo Fisher Article on Oct. 22

23 Oct 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 Oct 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 Oct 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 Oct 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 Oct 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 Oct 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 Oct 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 Oct 2025, 22:49 UTC

Acquisitions, Mergers, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 Oct 2025, 22:17 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 Oct 2025, 21:41 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 Oct 2025, 21:05 UTC

Earnings

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 Oct 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

23 Oct 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

23 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 Oct 2025, 20:35 UTC

Earnings

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 Oct 2025, 20:28 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 Oct 2025, 20:15 UTC

Market Talk
Earnings

Global Commodities Roundup: Market Talk

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Adj EPS $1.71

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q Sales $5.52B

23 Oct 2025, 20:10 UTC

Earnings

Newmont Mining 3Q EPS $1.67

23 Oct 2025, 20:09 UTC

Earnings

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 Oct 2025, 20:07 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

23 Oct 2025, 20:07 UTC

Market Talk
Earnings

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 Oct 2025, 20:07 UTC

Earnings

Blackstone Looks to IPOs for Investment Exits -- Update

23 Oct 2025, 20:05 UTC

Earnings

Intel 3Q Gross Margin 38.2% >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 Oct 2025, 20:04 UTC

Earnings

Intel: 4Q Guidance Excludes Altera >INTC

23 Oct 2025, 20:04 UTC

Earnings

Intel Sees 4Q Adj EPS 8c >INTC

Peer Comparison

Price change

Sana Biotechnology Inc Forecast

Price Target

By TipRanks

50% upside

12 Months Forecast

Average 8.25 USD  50%

High 12 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forSana Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

1.68 / 1.87Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

163 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat